Angiochem receives $7.5 million in Series C financing

Angiochem receives $7.5 million in Series C financing

Proceeds to support ongoing development of ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer

(Montreal – August 1, 2018) - Angiochem Inc. (“Angiochem”) announced today that it has secured a $7.5 million Series C financing to pursue its development plan.

Angiochem is currently developing ANG1005 for the treatment of leptomeningeal carcinomatosis from breast cancer, for which there are no approved therapeutic treatment options currently available. Angiochem’s Phase 3 clinical trial for ANG1005 is expected to start later this year.  “This is a significant development for Angiochem. With this latest financing, the company is on track to further develop ANG1005. This compound has already delivered promising results and now, we are gearing up for a pivotal Phase 3 trial that will hopefully lead to a long awaited therapeutic solution for patients with breast cancer who suffer from brain metastases and leptomeningeal carcinomatosis,” said John Huss, Executive Chairman of Angiochem. “This is an important, unmet medical need.”

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the brain blood barrier (BBB) to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.

Contact Information:

Crystal Quast

Bullseye Corporate

647-529-6364

Quast@BullseyeCorporate.com